Nitrogen-containing heterocyclic compounds, their preparation methods and their pharmaceutical applications

By synthesizing and applying nitrogen-containing heterocyclic compounds represented by general formula (IM), the need for selective inhibitors of PARP1 in the prior art has been addressed, achieving selective inhibition of PARP1 and therapeutic effects on cancer.

CN115403595BActive Publication Date: 2026-11-17JIANGSU HENGRUI MEDICINE CO LTD +1
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
CN202210585643.1
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2021-06-29
Filing Date
2022-05-26
Publication Date
2026-11-17
Estimated Expiration
2042-05-26

AI Technical Summary

Technical Problem

There is a need for effective and safe PARP inhibitors, especially PARP inhibitors selective for PARP1, for the treatment and prevention of cancer.

Method used

A nitrogen-containing heterocyclic compound of general formula (IM) and its pharmaceutically usable salt are provided. The compound is synthesized by a preparation method and used to prepare a PARP1 inhibitor for the treatment and prevention of cancer.

Benefits of technology

It achieves selective inhibition of PARP1, effectively kills tumor cells with homologous recombination defects, reduces toxicity, and provides an effective means of treating cancer.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN115403595B_ABST
    Figure CN115403595B_ABST
Patent Text Reader

Abstract

This disclosure relates to nitrogen-containing heterocyclic compounds, their preparation methods, and their pharmaceutical applications. Specifically, this disclosure relates to a nitrogen-containing heterocyclic compound represented by general formula (IM), its preparation method, pharmaceutical compositions containing such compounds, and their use as therapeutic agents, particularly as PARP1 inhibitors and for the treatment and / or prevention of cancer.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This disclosure pertains to the pharmaceutical field and relates to a nitrogen-containing heterocyclic compound, its preparation method, and its pharmaceutical applications. In particular, this disclosure relates to nitrogen-containing heterocyclic compounds of general formula (IM), their preparation methods, pharmaceutical compositions containing such compounds, and their use as PARP1 inhibitors and for the treatment and / or prevention of cancer. Background Technology

[0002] Poly(ADP-ribose) polymerase 1 (PARP1), first reported over 50 years ago, has since been found to play crucial roles in DNA repair, maintaining genome integrity, and regulating various metabolic and signal transduction processes. PARP1 catalyzes the transfer of ADP-ribose residues from NAD+ to target substrates, constructing a poly(ADP-ribose) (PAR) chain. The formation and clearance of PAR chains occur in almost all eukaryotic cells.

[0003] ADP-ribosylation is a post-translational modification of proteins widely present in various physiological and pathological processes. It refers to the binding of one or more ADP-ribose units to a specific site on a protein under the catalysis of an enzyme. PARP1 is the first member of the PARP superfamily, which consists of proteins homologous to PARP1 and currently has 17 members, four of which (PARP1, PARP2, PARP5A, and PARP5B) are capable of synthesizing PAR chains. Most other enzymes in the family can only construct a single ADP-ribose unit and are therefore classified as mono(ADP-ribosyl)ases (MARs).

[0004] PARP1 and PARP2 have been extensively studied for their roles in DNA damage repair. PARP1 is activated by DNA damage and catalyzes the movement of the poly(ADP-ribosyl) (PAR) chain toward target proteins. This post-translational modification, called poly-ADP-ribosylation (PARylation), mediates the recruitment of other DNA repair factors to the DNA damage site. After completing this recruitment, PARP auto-PARylation triggers the release of bound PARP from the DNA, allowing access to other DNA repair proteins to complete the repair. Therefore, PARP binding to the damaged site, its catalytic activity, and its eventual release from the DNA are all crucial steps in how cancer cells respond to DNA damage induced by chemotherapy and radiotherapy.

[0005] Inhibiting PARP family enzymes has been used as a strategy to selectively kill cancer cells by inactivating complementary DNA repair pathways. Numerous preclinical and clinical studies have shown that tumor cells with harmful alterations in the key tumor suppressor proteins BRCA1 or BRCA2, which are involved in double-strand DNA break (DSB) repair via harmful recombination (HR), are selectively sensitive to small molecules such as inhibitors of the PARP family of DNA repair enzymes. These tumors have insufficient homologous recombination repair (HRR) pathways and rely on the survival function of PARP enzymes. Although PARP inhibitor therapy primarily targets BRCA-mutated cancers, PARP inhibitors have been clinically tested in non-BRCA-mutated tumors that exhibit homologous recombination deficiency (HRD).

[0006] Compared to other PARP1 / 2 inhibitors, PARP inhibitors with enhanced selectivity for PARP1 can exhibit improved efficacy and reduced toxicity. We believe that strong selective inhibition of PARP1 will lead to PARP1 capture on DNA, resulting in DNA double-strand breaks (DSBs) through the collapse of the replication fork in S phase. PARP1-DNA capture is an effective mechanism for selectively killing tumor cells with HRD.

[0007] Therefore, there is an urgent clinical need for effective and safe PARP inhibitors, especially PARP inhibitors that are selective for PARP1.

[0008] The patent application for a PARP1 inhibitor has been published as WO2021013735A1. Summary of the Invention

[0009] The purpose of this disclosure is to provide a compound of general formula (IM) or a pharmaceutically acceptable salt thereof:

[0010]

[0011] in:

[0012] Ring A is a heteroaryl group;

[0013] Ring B is aryl or heteroaryl;

[0014] G 1 G 2 and G 3 Whether the same or different, and each independently constitutes a CR 6 Or nitrogen atoms;

[0015] R 0 R 1 and R 6 They may be the same or different, and each is independently selected from hydrogen atom, halogen, alkyl, alkoxy, haloalkyl, haloalkoxy, hydroxyalkyl, cyano, -NR 7aR 7b hydroxyl group, -C(O)R 8 -C(O)OR 8 -C(O)NR 7a R 7b -S(O) p R 8 cycloalkyl, heterocyclic, aryl, and heteroaryl, wherein the alkyl, alkoxy, cycloalkyl, heterocyclic, aryl, and heteroaryl groups are each independently and optionally selected from halogen, oxo, alkyl, alkoxy, haloalkyl, haloalkoxy, cyano, -NR 9a R 9b The substance is substituted by one or more substituents selected from hydroxyl, hydroxyalkyl, cycloalkyl, heterocyclic, aryl and heteroaryl;

[0016] Each R 2 They may be the same or different, and each is independently selected from hydrogen atom, halogen, alkyl, alkoxy, haloalkyl, haloalkoxy, cyano, -NR 7a R 7b hydroxyl and hydroxyalkyl;

[0017] Each R 3 They may be the same or different, and each is independently selected from halogen, alkyl, alkoxy, haloalkyl, haloalkoxy, hydroxyalkyl, cyano, -NR 7a R 7b hydroxyl group, -C(O)R 8 -C(O)OR 8 -C(O)NR 7a R 7b -S(O) p R 8 cycloalkyl, heterocyclic, aryl, and heteroaryl, wherein the alkyl, alkoxy, cycloalkyl, heterocyclic, aryl, and heteroaryl groups are each independently and optionally selected from halogen, oxo, alkyl, alkoxy, haloalkyl, haloalkoxy, cyano, -NR 9a R 9b The substance is substituted by one or more substituents selected from hydroxyl, hydroxyalkyl, cycloalkyl, heterocyclic, aryl and heteroaryl;

[0018] R 7a R 7b R 9a R 9b They may be the same or different, and each is independently selected from hydrogen atoms, alkyl, hydroxyalkyl, cycloalkyl and heterocyclic groups, wherein each of the alkyl, cycloalkyl and heterocyclic groups is independently optionally substituted by one or more substituents selected from halogen, alkyl, alkoxy, haloalkyl and haloalkoxy;

[0019] Or R 7a and R 7bR 9a and R 9b Together with the attached nitrogen atom, a heterocyclic group is formed, wherein the formed heterocyclic group is optionally substituted by one or more substituents selected from halogen, oxo, alkyl, alkoxy, haloalkyl, haloalkoxy, cyano, amino, nitro, hydroxy, hydroxyalkyl, cycloalkyl, heterocyclic, aryl, and heteroaryl.

[0020] R 8 The group is selected from hydrogen atoms, alkyl, hydroxyalkyl, cycloalkyl and heterocyclic groups, wherein each of the alkyl, cycloalkyl and heterocyclic groups is independently and optionally substituted by one or more substituents selected from halogen, alkyl, alkoxy, haloalkyl and haloalkoxy;

[0021] p is 0, 1, or 2;

[0022] m is 0, 1, or 2;

[0023] n is 0, 1, or 2;

[0024] s is 0, 1, 2, 3, or 4; and

[0025] t can be 0, 1, 2 or 3.

[0026] In some embodiments of this disclosure, the compound represented by general formula (IM) or a pharmaceutically acceptable salt thereof is a compound represented by general formula (I) or a pharmaceutically acceptable salt thereof:

[0027]

[0028] in:

[0029] Ring A is a heteroaryl group;

[0030] Ring B is aryl or heteroaryl;

[0031] G 1 G 2 and G 3 Whether the same or different, and each independently constitutes a CR 6 Or nitrogen atoms;

[0032] R 1 and R 6 They may be the same or different, and each is independently selected from hydrogen atom, halogen, alkyl, alkoxy, haloalkyl, haloalkoxy, hydroxyalkyl, cyano, -NR 7a R 7b hydroxyl group, -C(O)R 8 -C(O)OR 8 -C(O)NR 7a R 7b -S(O) p R 8cycloalkyl, heterocyclic, aryl, and heteroaryl, wherein the alkyl, alkoxy, cycloalkyl, heterocyclic, aryl, and heteroaryl groups are each independently and optionally selected from halogen, oxo, alkyl, alkoxy, haloalkyl, haloalkoxy, cyano, -NR 9a R 9b The substance is substituted by one or more substituents selected from hydroxyl, hydroxyalkyl, cycloalkyl, heterocyclic, aryl and heteroaryl;

[0033] Each R 2 They may be the same or different, and each is independently selected from hydrogen atom, halogen, alkyl, alkoxy, haloalkyl, haloalkoxy, cyano, -NR 7a R 7b hydroxyl and hydroxyalkyl;

[0034] Each R 3 They may be the same or different, and each is independently selected from halogen, alkyl, alkoxy, haloalkyl, haloalkoxy, hydroxyalkyl, cyano, -NR 7a R 7b hydroxyl group, -C(O)R 8 -C(O)OR 8 -C(O)NR 7a R 7b -S(O) p R 8 cycloalkyl, heterocyclic, aryl, and heteroaryl, wherein the alkyl, alkoxy, cycloalkyl, heterocyclic, aryl, and heteroaryl groups are each independently and optionally selected from halogen, oxo, alkyl, alkoxy, haloalkyl, haloalkoxy, cyano, -NR 9a R 9b The substance is substituted by one or more substituents selected from hydroxyl, hydroxyalkyl, cycloalkyl, heterocyclic, aryl and heteroaryl;

[0035] R 7a R 7b R 9a R 9b They may be the same or different, and each is independently selected from hydrogen atoms, alkyl, hydroxyalkyl, cycloalkyl and heterocyclic groups, wherein each of the alkyl, cycloalkyl and heterocyclic groups is independently optionally substituted by one or more substituents selected from halogen, alkyl, alkoxy, haloalkyl and haloalkoxy;

[0036] Or R 7a and R 7b R 9a and R 9b Together with the attached nitrogen atom, a heterocyclic group is formed, wherein the formed heterocyclic group is optionally substituted by one or more substituents selected from halogen, oxo, alkyl, alkoxy, haloalkyl, haloalkoxy, cyano, amino, nitro, hydroxy, hydroxyalkyl, cycloalkyl, heterocyclic, aryl, and heteroaryl.

[0037] R 8 The group is selected from hydrogen atoms, alkyl, hydroxyalkyl, cycloalkyl and heterocyclic groups, wherein each of the alkyl, cycloalkyl and heterocyclic groups is independently and optionally substituted by one or more substituents selected from halogen, alkyl, alkoxy, haloalkyl and haloalkoxy;

[0038] p is 0, 1, or 2;

[0039] m is 0, 1, or 2;

[0040] n is 0, 1, or 2;

[0041] s is 0, 1, 2, 3, or 4; and

[0042] t can be 0, 1, 2 or 3.

[0043] In some preferred embodiments of this disclosure, the compound represented by general formula (IM) or general formula (I) or its pharmaceutically usable salt, wherein ring A is a 5- or 6-membered heteroaryl group containing at least one nitrogen atom; preferably, ring A is a pyrazolyl group.

[0044] In some preferred embodiments of this disclosure, the compounds represented by general formula (IM), general formula (I), or pharmaceutically acceptable salts thereof, wherein... Selected from

[0045] Preferably, for More preferably, for Among them, R 2 m and n are as defined in the general formula (IM).

[0046] In some preferred embodiments of this disclosure, the compound represented by general formula (IM), general formula (I), or a pharmaceutically acceptable salt thereof, wherein m is 1 or 2; preferably, m is 1.

[0047] In some preferred embodiments of this disclosure, the compound represented by general formula (IM), general formula (I), or a pharmaceutically acceptable salt thereof, wherein n is 1 or 2; preferably, n is 1.

[0048] In some preferred embodiments of this disclosure, the compound represented by the general formula (IM) or a pharmaceutically acceptable salt thereof is a compound represented by the general formula (IIM) or a pharmaceutically acceptable salt thereof:

[0049]

[0050] in:

[0051] X is a nitrogen atom and Y is a CR atom. 2 Or X is CR 2 And Y is a nitrogen atom;

[0052] n is 1 or 2;

[0053] Rings B and G 1 To G 3 R 0 To R 3 And t are as defined in the general formula (IM).

[0054] In some embodiments of this disclosure, the compound represented by the general formula (IM), the compound represented by the general formula (IIM), or a pharmaceutically acceptable salt thereof, wherein R 0 Selected from hydrogen atoms, halogens, C 1-6 Alkyl and C 1-6 Halogenated alkyl; preferably, R 0 It is a hydrogen atom or a halogen; more preferably, R 0 It is a hydrogen atom or F; most preferably, R 0 It is a hydrogen atom.

[0055] In some preferred embodiments of this disclosure, the compounds represented by general formula (IM), general formula (I), and general formula (IIM), or pharmaceutically acceptable salts thereof, are compounds represented by general formula (II) or pharmaceutically acceptable salts thereof:

[0056]

[0057] in:

[0058] X is a nitrogen atom and Y is a CR atom. 2 Or X is CR 2 And Y is a nitrogen atom;

[0059] n is 1 or 2;

[0060] Rings B and G 1 To G 3 R 1 To R 3 And t are as defined in the general formula (IM).

[0061] In some preferred embodiments of this disclosure, the compounds represented by general formulas (IM), (I), (IIM), and (II), or pharmaceutically acceptable salts thereof, wherein G 1 For CH, G 2 For nitrogen atoms, G 3 For CR 6 Or G 1 and G 2 For CH, G 3 For nitrogen atoms; or G 1 For nitrogen atoms, G2 For CH, G 3 For CR 6 Preferably, G 1 For CH, G 2 For nitrogen atoms, G 3 For CR 6 ;where R 6 As defined in the general formula (IM).

[0062] In some preferred embodiments of this disclosure, the compounds represented by general formulas (IM), (I), (IIM), and (II), or pharmaceutically acceptable salts thereof, wherein R 6 Selected from hydrogen atoms, halogens, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Haloalkyl, C 1-6 Halogenated alkoxy groups and C 1-6 Hydroxyalkyl; preferably, R 6 Selected from hydrogen atoms, halogens, C 1-6 Alkyl and C 1-6 Halogenated alkyl; more preferably, R 6 It is a hydrogen atom.

[0063] In some preferred embodiments of this disclosure, the compounds represented by general formula (IM), general formula (I), general formula (IIM), and general formula (II), or pharmaceutically acceptable salts thereof, wherein ring B is a 6- to 10-membered aryl or a 5- to 10-membered heteroaryl; preferably, ring B is a phenyl or a 6-membered heteroaryl; more preferably, ring B is a pyridyl.

[0064] In some preferred embodiments of this disclosure, the compounds represented by general formula (IM), general formula (I), general formula (IIM), and general formula (II) or their pharmaceutically usable salts are used, wherein t is 1 or 2; preferably, t is 1.

[0065] In some preferred embodiments of this disclosure, the compounds represented by general formulas (IM), (I), (IIM), and (II), or pharmaceutically acceptable salts thereof, wherein R 3 Selected from halogens, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Haloalkyl, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, cyano, -NR 7a R 7b hydroxyl group, -C(O)R 8 -C(O)OR 8 and -C(O)NR 7a R 7b Preferably, R 3-C(O)NR 7a R 7b ;where R 7a R 7b and R 8 As defined in the general formula (IM).

[0066] In some preferred embodiments of this disclosure, the compounds represented by general formula (IM), general formula (I), general formula (IIM), and general formula (II), or pharmaceutically acceptable salts thereof, are compounds represented by general formula (III) or pharmaceutically acceptable salts thereof:

[0067]

[0068] in:

[0069] X is a nitrogen atom and Y is a CR atom. 2 Or X is CR 2 And Y is a nitrogen atom;

[0070] n is 1 or 2;

[0071] R 1 R 2 R 7a and R 7b As defined in the general formula (IM).

[0072] In some preferred embodiments of this disclosure, the compounds represented by general formulas (IM), (I), (IIM), (II), and (III), or their pharmaceutically acceptable salts, wherein R 1 Selected from hydrogen atoms, halogens, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Haloalkyl, C 1-6 Halogenated alkoxy groups and C 1-6 Hydroxyalkyl; preferably, R 1 C 1-6 Alkyl; more preferably, R 1 It is an ethyl group.

[0073] In some preferred embodiments of this disclosure, the compounds represented by general formulas (IM), (I), (IIM), (II), and (III), or their pharmaceutically acceptable salts, wherein R 2 Selected from hydrogen atoms, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Haloalkyl, C 1-6 Halogenated alkoxy groups and C 1-6 Hydroxyalkyl; preferably, R 2 Selected from hydrogen atoms, C 1-6 Alkyl and C1-6 Hydroxyalkyl; preferably, R 2 It is a hydrogen atom.

[0074] In some preferred embodiments of this disclosure, the compound represented by general formula (IM), general formula (I), or a pharmaceutically acceptable salt thereof, wherein s is 0 or 1; preferably, s is 0.

[0075] In some preferred embodiments of this disclosure, the compounds represented by general formulas (IM), (I), (IIM), (II), and (III), or their pharmaceutically acceptable salts, wherein R 7a and R 7b Whether the atoms are the same or different, and each is independently selected from hydrogen atoms, C atoms 1-6 Alkyl, C 1-6 Hydroxyalkyl, 3- to 8-membered cycloalkyl and 3- to 8-membered heterocyclic groups; preferably, R 7a and R 7b They may be the same or different, and each is independently a hydrogen atom or a carbon atom. 1-6 Alkyl; more preferably, R 7a and R 7b They may be the same or different, and each is independently a hydrogen atom or a methyl group.

[0076] In some preferred embodiments of this disclosure, the compounds represented by general formulas (IIM), (II), and (III), or their pharmaceutically acceptable salts, wherein... for Preferably, for Among them, R 2 And n is as defined in the general formula (IIM).

[0077] In some preferred embodiments of this disclosure, the compound represented by the general formula (IIM) or a pharmaceutically acceptable salt thereof, G 1 For CH, G 2 For nitrogen atoms, G 3 For CR 6 ;R 6 Selected from hydrogen atoms, halogens, C 1-6 Alkyl and C 1-6 Haloalkyl; ring B is phenyl or 6-membered heteroaryl; t is 1; R 3 -C(O)NR 7a R 7b ;R 7a and R 7b They may be the same or different, and each is independently a hydrogen atom or a carbon atom. 1-6 Alkyl group; n is 1 or 2; X is a nitrogen atom and Y is a CR atom. 2 Or X is CR 2 And Y is a nitrogen atom; R 2Selected from hydrogen atoms, C 1-6 Alkyl and C 1-6 Hydroxyalkyl; R 0 It is a hydrogen atom or a halogen; and R 1 C 1-6 alkyl.

[0078] In some preferred embodiments of this disclosure, the compound represented by general formula (II) or a pharmaceutically acceptable salt thereof, G 1 For CH, G 2 For nitrogen atoms, G 3 For CR 6 ;R 6 Selected from hydrogen atoms, halogens, C 1-6 Alkyl and C 1-6 Haloalkyl; ring B is phenyl or 6-membered heteroaryl; t is 1; R 3 -C(O)NR 7a R 7b ;R 7a and R 7b They may be the same or different, and each is independently a hydrogen atom or a carbon atom. 1-6 Alkyl group; n is 1 or 2; X is a nitrogen atom and Y is a CR atom. 2 Or X is CR 2 And Y is a nitrogen atom; R 2 Selected from hydrogen atoms, C 1-6 Alkyl and C 1-6 Hydroxyalkyl; and R 1 C 1-6 alkyl.

[0079] Table A lists typical compounds disclosed herein, including but not limited to:

[0080]

[0081]

[0082] Another aspect of this disclosure relates to compounds of the general formula (IIMa) or salts thereof:

[0083]

[0084] in:

[0085] R 3 -C(O)NR 7a R 7b ;

[0086] R 7a The group is selected from alkyl, hydroxyalkyl, cycloalkyl and heterocyclic groups, wherein each of the alkyl, cycloalkyl and heterocyclic groups is independently and optionally substituted by one or more substituents selected from halogen, alkyl, alkoxy, haloalkyl and haloalkoxy groups;

[0087] t is 1, 2, or 3;

[0088] X, Y, ring B, R 7b And n is as defined in the general formula (IIM).

[0089] Another aspect of this disclosure relates to compounds of general formula (IIIa) or salts thereof:

[0090]

[0091] in:

[0092] X, Y, R 7a R 7b And n is as defined in general formula (III).

[0093] Table B lists typical intermediate compounds disclosed herein, including but not limited to:

[0094]

[0095]

[0096] Another aspect of this disclosure relates to a method for preparing a compound of general formula (IM) or a pharmaceutically acceptable salt thereof, the method comprising:

[0097]

[0098] A compound of general formula (IMa) or a salt thereof (preferably a hydrochloride salt) undergoes a nucleophilic substitution reaction with a compound of general formula (IIMb) to give a compound of general formula (IM) or a pharmaceutically usable salt thereof.

[0099] in:

[0100] L is a halogen, preferably a chlorine atom;

[0101] G 1 G 2 G 3 Ring A, Ring B, R 0 R 1 R 2 R 3 , s, t, m and n are as defined in the general formula (IM).

[0102] Another aspect of this disclosure relates to a method for preparing a compound of general formula (I) or a pharmaceutically acceptable salt thereof, the method comprising:

[0103]

[0104] A compound of general formula (IMa) or a salt thereof (preferably a hydrochloride salt) undergoes a nucleophilic substitution reaction with a compound of general formula (IIb) to give a compound of general formula (I) or a pharmaceutically usable salt thereof;

[0105] in:

[0106] L is a halogen, preferably a chlorine atom;

[0107] G 1 G 2 G 3 Ring A, Ring B, R 1 R 2 R 3 , s, t, m and n are as defined in general formula (I).

[0108] Another aspect of this disclosure relates to a method for preparing a compound of general formula (IIM) or a pharmaceutically acceptable salt thereof, the method comprising:

[0109]

[0110] A compound of general formula (IIMa) or a salt thereof (preferably a hydrochloride salt) undergoes a nucleophilic substitution reaction with a compound of general formula (IIMb) to give a compound of general formula (IIM) or a pharmaceutically usable salt thereof.

[0111] in:

[0112] L is a halogen, preferably a chlorine atom;

[0113] G 1 G 2 G 3 X, Y, ring B, R 0 R 1 R 3 , t and n are as defined in the general formula (IIM).

[0114] Another aspect of this disclosure relates to a method for preparing a compound of general formula (II) or a pharmaceutically acceptable salt thereof, the method comprising:

[0115]

[0116] A compound of general formula (IIMa) or a salt thereof (preferably a hydrochloride salt) undergoes a nucleophilic substitution reaction with a compound of general formula (IIb) to give a compound of general formula (II) or a pharmaceutically usable salt thereof;

[0117] in:

[0118] L is a halogen, preferably a chlorine atom;

[0119] G 1 G 2 G3 X, Y, ring B, R 1 R 3 , t and n are as defined in general formula (II).

[0120] Another aspect of this disclosure relates to a method for preparing a compound of general formula (III) or a pharmaceutically acceptable salt thereof, the method comprising:

[0121]

[0122] A compound of general formula (IIIa) or a salt thereof (preferably a hydrochloride salt) undergoes a nucleophilic substitution reaction with a compound of general formula (V) to give a compound of general formula (III) or a pharmaceutically usable salt thereof;

[0123] in:

[0124] L is a halogen, preferably a chlorine atom;

[0125] X, Y, R 1 R 7a R 7b And n is as defined in general formula (III).

[0126] Another aspect of this disclosure relates to a pharmaceutical composition comprising compounds of general formulas (IM), (I), (IIM), (II), (III) of this disclosure and those shown in Table A, or pharmaceutically acceptable salts thereof, and one or more pharmaceutically acceptable carriers, diluents, or excipients.

[0127] This disclosure further relates to the use of compounds of general formula (IM), general formula (I), general formula (IIM), general formula (II), general formula (III) and those shown in Table A, or pharmaceutically acceptable salts thereof, or pharmaceutical compositions comprising them, in the preparation of PARP1 inhibitors.

[0128] This disclosure further relates to the use of compounds of formula (IM), formula (I), formula (IIM), formula (II), formula (III) and those shown in Table A, or pharmaceutically acceptable salts thereof, or pharmaceutical compositions comprising them, in the preparation of medicaments for the treatment and / or prevention of cancer, essential thrombocythemia, or polycythemia vera.

[0129] This disclosure further relates to a method of inhibiting PARP1, comprising administering to a patient a therapeutically effective amount of a compound of formula (IM), formula (I), formula (IIM), formula (II), formula (III), and the compound shown in Table A, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the compound.

[0130] This disclosure further relates to a method of treating and / or preventing cancer, essential thrombocythemia, or polycythemia vera, comprising administering to a patient a therapeutically effective amount of a compound of formula (IM), formula (I), formula (IIM), formula (II), formula (III), and the compound shown in Table A, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the compound.

[0131] This disclosure further relates to a compound of formula (IM), formula (I), formula (IIM), formula (II), formula (III) and shown in Table A, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising thereof, which is used as a medicine.

[0132] This disclosure further relates to a compound of formula (IM), formula (I), formula (IIM), formula (II), formula (III) and shown in Table A, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising thereof, which is used as a PARP1 inhibitor.

[0133] This disclosure further relates to a compound of formula (IM), formula (I), formula (IIM), formula (II), formula (III) and shown in Table A, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising thereof, used as a medicament for the treatment and / or prevention of cancer, essential thrombocythemia, or polycythemia vera.

[0134] The cancers described in this disclosure are selected from breast cancer, ovarian cancer, pancreatic cancer, prostate cancer, gastric cancer, colorectal cancer (such as colon cancer and rectal cancer), lung cancer, kidney cancer, liver cancer (such as hepatocellular carcinoma), cervical cancer, endometrial cancer, myeloma (such as multiple myeloma), leukemia (such as acute leukemia, chronic leukemia, myeloid leukemia, myelofibrosis, erythroleukemia), lymphoma (such as diffuse large B-cell lymphoma, Hodgkin lymphoma, non-Hodgkin lymphoma, T-cell or B-cell lymphoid malignancies, follicular lymphoma), acoustic neuroma, basal cell carcinoma, bile duct cancer, bladder cancer, brain cancer, bronchial cancer, sarcoma (such as chondrosarcoma, fibrosarcoma, leiomyosarcoma, liposarcoma, lymphangiosarcoma, myxosarcoma, osteoblastic sarcoma, and striae). The cancers include sarcomas, Ewing's tumors, chordomas, choriocarcinomas, craniopharyngiomas, cystadenocarcinomas, embryonal carcinomas, hemangioendotheliomas, ependymomas, epithelial carcinomas, esophageal cancers, testicular cancers, gliomas, heavy chain disease, hemangioblastomas, medullary carcinomas, medulloblastomas, melanomas, meningiomas, mesotheliomas, neuroblastomas, midline carcinomas of nucleoid fibroblasts (NUTs), gliomas, bone cancers, nasopharyngeal carcinomas, oral cancers, thyroid cancers, pineal tumors, retinoblastomas, sebaceous gland carcinomas, seminomas, skin cancers, squamous cell carcinomas, synovial tumors, sweat gland carcinomas, Waldenström's macroglobulinemia, and Wilms' tumor; the sarcoma is preferably Ewing's tumor; preferably, the cancers are selected from breast cancer, ovarian cancer, pancreatic cancer, prostate cancer, gastric cancer, colorectal cancer, and lung cancer.

[0135] The active compounds can be formulated into forms suitable for administration via any appropriate route, using one or more pharmaceutically acceptable carriers through conventional methods. Therefore, the active compounds of this disclosure can be formulated into various dosage forms for oral administration, injection (e.g., intravenous, intramuscular, or subcutaneous), inhalation, or insufflation. The compounds of this disclosure can also be formulated into dosage forms such as tablets, hard or soft capsules, aqueous or oily suspensions, emulsions, injections, dispersible powders or granules, suppositories, lozenges, or syrups.

[0136] As a general guideline, the active compound is preferably expressed in a unit dose manner, or in a manner that allows the patient to self-administer a single dose. The unit dose of the disclosed compound or composition may be expressed as a tablet, capsule, sachet, bottled liquid, powder, granule, lozenge, suppository, regenerated powder, or liquid formulation. Suitable unit doses may range from 0.1 to 1000 mg.

[0137] In addition to the active compound, the pharmaceutical compositions disclosed herein may contain one or more excipients selected from the following: fillers (diluents), binders, wetting agents, disintegrants, or excipients. Depending on the method of administration, the composition may contain 0.1 to 99% by weight of the active compound.

[0138] Tablets contain an active ingredient and non-toxic, pharmaceutically acceptable excipients suitable for tablet preparation, used for mixing. These excipients may be inert excipients, granulating agents, disintegrants, binders, and lubricants. These tablets may be uncoated or coated using known techniques that mask the taste of the drug or delay disintegration and absorption in the gastrointestinal tract, thus providing sustained release over a longer period.

[0139] Oral formulations can also be provided using soft gelatin capsules in which the active ingredient is mixed with an inert solid diluent or in which the active ingredient is mixed with a water-soluble carrier or an oil solvent.

[0140] Aqueous suspensions contain active substances and excipients suitable for preparing aqueous suspensions, used for mixing. These excipients are suspending agents, dispersing agents, or wetting agents. Aqueous suspensions may also contain one or more preservatives, one or more coloring agents, one or more flavoring agents, and one or more sweeteners.

[0141] Oil suspensions are prepared by suspending the active ingredient in vegetable or mineral oil. Oil suspensions may contain thickeners. Sweeteners and flavoring agents mentioned above may be added to provide palatable formulations. These compositions may be preserved by adding antioxidants.

[0142] The pharmaceutical compositions disclosed herein may also be in the form of an oil-in-water emulsion. The oil phase may be a vegetable oil, a mineral oil, or a mixture thereof. Suitable emulsifiers may be naturally occurring phospholipids, and the emulsion may also contain sweeteners, flavoring agents, preservatives, and antioxidants. Such formulations may also contain modifiers, preservatives, colorants, and antioxidants.

[0143] The pharmaceutical compositions disclosed herein may be in the form of sterile injectable aqueous solutions. Acceptable solvents or media that can be used include water, Ringer's solution, and isotonic sodium chloride solution. The sterile injectable formulation may be a sterile injectable oil-in-water microemulsion in which the active ingredient is dissolved in the oil phase, which can be injected into the patient's bloodstream via local large-volume injection. Alternatively, the solution and microemulsion are preferably administered in a manner that maintains a constant circulating concentration of the compounds disclosed herein. To maintain such a constant concentration, a continuous intravenous delivery device can be used. An example of such a device is the Deltec CADD-PLUS™ 5400 intravenous infusion pump.

[0144] The pharmaceutical compositions disclosed herein may be in the form of sterile injectable aqueous or oil suspensions for intramuscular and subcutaneous administration. These suspensions may be formulated using suitable dispersants or wetting agents and suspending agents as described above, according to known techniques. The sterile injectable formulations may also be sterile injectable solutions or suspensions prepared in parenteral-acceptable, non-toxic diluents or solvents. Furthermore, sterile fixative oils may be conveniently used as solvents or suspension media. For this purpose, any blended fixative oil may be used. Additionally, fatty acids may also be used to prepare injectable formulations.

[0145] The disclosed compounds can be administered in suppository form for rectal administration. These pharmaceutical compositions can be prepared by mixing the drug with a suitable, non-irritating excipient that is solid at normal temperatures but liquid in the rectum, and thus dissolves in the rectum to release the drug.

[0146] The compounds disclosed herein can be administered by adding water to prepare water-soluble dispersible powders and granules. These pharmaceutical compositions can be prepared by mixing the active ingredient with a dispersant or wetting agent, a suspending agent, or one or more preservatives.

[0147] As is well known to those skilled in the art, the dosage of a drug depends on a variety of factors, including but not limited to: the activity of the specific compound used, the patient's age, the patient's weight, the patient's health status, the patient's behavior, the patient's diet, the timing of administration, the route of administration, the rate of excretion, the combination of drugs, the severity of the disease, etc.; in addition, the optimal treatment mode, such as the treatment pattern, the daily dosage of the compound, or the type of medicinal salt can be validated based on conventional treatment protocols.

[0148] Terminology Explanation

[0149] Unless otherwise stated, the terms used in the specification and claims have the following meanings.

[0150] The term "alkyl" refers to a saturated aliphatic hydrocarbon group, which is a straight-chain or branched group containing 1 to 20 carbon atoms, preferably an alkyl group having 1 to 12 (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, and 12) carbon atoms (i.e., C12). 1-12 Alkyl groups, more preferably alkyl groups having 1 to 6 carbon atoms (i.e., C1646-C ... 1-6 Alkyl groups). Non-limiting examples include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, n-pentyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl, 1-ethylpropyl, 2-methylbutyl, 3-methylbutyl, n-hexyl, 1-ethyl-2-methylpropyl, 1,1,2-trimethylpropyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 2,2-dimethylbutyl, 1,3-dimethylbutyl, 2-ethylbutyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 2,3-dimethylbutyl, n-heptyl, 2-methylhexyl, 3-methylhexyl, 4-methylhexyl, 5-methylhexyl, 2, 3-Dimethylpentyl, 2,4-Dimethylpentyl, 2,2-Dimethylpentyl, 3,3-Dimethylpentyl, 2-Ethylpentyl, 3-Ethylpentyl, n-Octyl, 2,3-Dimethylhexyl, 2,4-Dimethylhexyl, 2,5-Dimethylhexyl, 2,2-Dimethylhexyl, 3,3-Dimethylhexyl, 4,4-Dimethylhexyl, 2-Ethylhexyl, 3-Ethylhexyl, 4-Ethylhexyl, 2-Methyl-2-Ethylpentyl, 2-Methyl-3-Ethylpentyl, n-Nonyl, 2-Methyl-2-Ethylhexyl, 2-Methyl-3-Ethylhexyl, 2,2-Diethylpentyl, n-Decyl, 3,3-Diethylhexyl, 2,2-Diethylhexyl, and their various branched isomers, etc. Alkyl groups can be substituted or unsubstituted. When substituted, they can be substituted at any usable connection point. The substituents are preferably selected from one or more of the following: D atom, halogen, alkoxy, haloalkyl, haloalkoxy, cycloalkyloxy, heterocyclic oxy, hydroxy, hydroxyalkyl, cyano, amino, nitro, cycloalkyl, heterocyclic, aryl, and heteroaryl.

[0151] The term "alkylene" refers to a saturated straight-chain or branched aliphatic hydrocarbon group, which is a residue derived from a parent alkane by removing two hydrogen atoms from the same carbon atom or two different carbon atoms. It is a straight-chain or branched group containing 1 to 20 carbon atoms, preferably having 1 to 12 (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, and 12) carbon atoms (i.e., C64). 1-12 Alkylenes, more preferably alkylenes having 1 to 6 carbon atoms (i.e., C16-164 ... 1-6Alkylenes. Non-limiting examples of alkylenes include, but are not limited to, methylene (-CH2-), 1,1-ethylene (-CH(CH3)-), 1,2-ethylene (-CH2CH2)-, 1,1-propylene (-CH(CH2CH3)-), 1,2-propylene (-CH2CH(CH3)-), 1,3-propylene (-CH2CH2CH2-), 1,4-butylene (-CH2CH2CH2CH2-), etc. Alkylenes can be substituted or unsubstituted, and when substituted, they can be substituted at any usable linking point. Substituents are preferably selected from one or more of alkenyl, alkynyl, alkoxy, haloalkoxy, cycloalkyloxy, heterocyclic alkoxy, alkylthio, alkylamino, halogen, mercapto, hydroxyl, nitro, cyano, cycloalkyl, heterocyclic, aryl, heteroaryl, cycloalkoxy, heterocyclic alkoxy, cycloalkylthio, heterocyclic alkylthio, and oxo.

[0152] The term "alkenyl" refers to an alkyl group containing at least one carbon-carbon double bond in a molecule, wherein the definition of an alkyl group is as described above. Preferably, it is an alkenyl group containing 2 to 12 (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, and 12) carbon atoms (i.e., C16-C16). 2-12 Alkenyl), more preferably alkenyl containing 2 to 6 carbon atoms (i.e., C14-C ... 2-6 Alkenyl). The alkenyl group can be substituted or unsubstituted, and when substituted, the substituent is preferably selected from one or more of alkoxy, halogen, haloalkyl, haloalkoxy, cycloalkyloxy, heterocyclicoxy, hydroxy, hydroxyalkyl, cyano, amino, nitro, cycloalkyl, heterocyclic, aryl and heteroaryl.

[0153] The term "alkynyl" refers to an alkyl group containing at least one carbon-carbon triple bond in a molecule, wherein the definition of alkyl is as described above. Preferably, the alkynyl group contains 2 to 12 (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, and 12) carbon atoms (i.e., C16, C26, C36, C46, ​​C56, C66, C76, C86, C96, C1 ... 2-12 Alkyne group), more preferably an alkyne group containing 2 to 6 carbon atoms (i.e., C12-C64 ... 2-6 (Alkyne group). The alkynyl group can be substituted or unsubstituted, and when substituted, the substituent is preferably selected from one or more of alkoxy, halogen, haloalkyl, haloalkoxy, cycloalkyloxy, heterocyclicoxy, hydroxy, hydroxyalkyl, cyano, amino, nitro, cycloalkyl, heterocyclic, aryl, and heteroaryl.

[0154] The term "cycloalkyl" refers to a saturated or partially unsaturated monocyclic or polycyclic cyclic hydrocarbon substituent, wherein the cycloalkyl ring contains 3 to 20 carbon atoms, preferably 3 to 12 (e.g., 3, 4, 5, 6, 7, 8, 9, 10, 11, and 12) carbon atoms (i.e., 3 to 12-membered cycloalkyl), more preferably 3 to 8 carbon atoms (i.e., 3 to 8-membered cycloalkyl), and more preferably 3 to 6 carbon atoms (i.e., 3 to 6-membered cycloalkyl). Non-limiting examples of monocyclic cycloalkyl include cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cyclohexadienyl, cycloheptyl, cyclohepttrienyl, cyclooctyl, etc.; polycyclic cycloalkyl includes spirocycloalkyl, fused cycloalkyl, and bridged cycloalkyl.

[0155] The term "spirocycloalkyl" refers to a 5- to 20-membered polycyclic group that shares a single carbon atom (called a spiro atom) between its rings, and may contain one or more double bonds. Preferably, it is 6- to 14-membered (i.e., 6- to 14-membered spirocycloalkyl), more preferably 7- to 10-membered (e.g., 7, 8, 9, or 10-membered) (i.e., 7- to 10-membered spirocycloalkyl). Spirocycloalkyl groups are classified as monospirocycloalkyl or polyspirocycloalkyl (e.g., bispirocycloalkyl) based on the number of shared spiro atoms between the rings, with monospirocycloalkyl and bispirocycloalkyl being preferred. More preferably, it is 3 / 5-membered, 3 / 6-membered, 4 / 4-membered, 4 / 5-membered, 4 / 6-membered, 5 / 5-membered, 5 / 6-membered, or 6 / 6-membered monospirocycloalkyl. Non-limiting examples of spirocycloalkyl groups include:

[0156]

[0157] The term "fused cycloalkyl" refers to a 5- to 20-membered polycyclic group in which each ring in the system shares an adjacent pair of carbon atoms with other rings in the system, wherein one or more rings may contain one or more double bonds. Preferably, it is 6- to 14-membered (i.e., 6- to 14-membered fused cycloalkyl), more preferably 7- to 10-membered (e.g., 7, 8, 9, or 10-membered) (i.e., 7- to 10-membered fused cycloalkyl). Depending on the number of constituent rings, it can be classified as bicyclic, tricyclic, tetracyclic, or polycyclic fused cycloalkyl, preferably bicyclic or tricyclic, more preferably 3- / 4-membered, 3- / 5-membered, 3- / 6-membered, 4- / 4-membered, 4- / 5-membered, 4- / 6-membered, 5- / 4-membered, 5- / 5-membered, 5- / 6-membered, 6- / 3-membered, 6- / 4-membered, 6- / 5-membered, and 6- / 6-membered bicyclic alkyl. Non-limiting examples of fused cycloalkyl include:

[0158]

[0159] The term "bridged cycloalkyl" refers to a 5- to 20-membered polycyclic carbon group in which any two rings share two non-directly bonded carbon atoms, and may contain one or more double bonds. Preferably, it is 6- to 14-membered (i.e., 6- to 14-membered bridged cycloalkyl), more preferably 7- to 10-membered (e.g., 7, 8, 9, or 10-membered) (i.e., 7- to 10-membered bridged cycloalkyl). Depending on the number of constituent rings, it can be classified as bicyclic, tricyclic, tetracyclic, or polycyclic bridged cycloalkyl, preferably bicyclic, tricyclic, or tetracyclic, more preferably bicyclic or tricyclic. Non-limiting examples of bridged cycloalkyl include:

[0160]

[0161] The cycloalkyl ring includes cycloalkyl groups (including monocyclic cycloalkyl, spirocyclic cycloalkyl, fused cycloalkyl, and bridged cycloalkyl) fused to an aryl, heteroaryl, or heterocyclic alkyl ring as described above, wherein the ring attached to the parent structure is a cycloalkyl group. Non-limiting examples include... etc.; preferred

[0162] The cycloalkyl group can be substituted or unsubstituted. When substituted, it can be substituted at any usable connection point. The substituent is preferably selected from one or more of halogen, alkyl, alkoxy, haloalkyl, haloalkoxy, cycloalkyloxy, heterocyclic oxy, hydroxy, hydroxyalkyl, cyano, amino, nitro, cycloalkyl, heterocyclic, aryl, and heteroaryl.

[0163] The term "alkoxy" refers to -O-(alkyl), where alkyl is defined as described above. Non-limiting examples of alkoxy groups include methoxy, ethoxy, propoxy, and butoxy. Alkoxy groups can be optionally substituted or unsubstituted, and when substituted, the substituents are preferably selected from D atoms, halogens, alkoxy groups, haloalkyl groups, haloalkoxy groups, cycloalkyloxy groups, heterocyclic oxy groups, hydroxyl groups, hydroxyalkyl groups, cyano groups, amino groups, nitro groups, cycloalkyl groups, heterocyclic groups, aryl groups, and heteroaryl groups.

[0164] The term "heterocyclic group" refers to a saturated or partially unsaturated monocyclic or polycyclic substituent containing 3 to 20 ring atoms, one or more of which are heteroatoms selected from nitrogen, oxygen and sulfur, wherein the sulfur may optionally be oxidized (i.e., forming sulfoxide or sulfone), but does not include the ring moiety of -OO-, -OS- or -SS-, and the remaining ring atoms are carbon. Preferably, it comprises 3 to 12 (e.g., 3, 4, 5, 6, 7, 8, 9, 10, 11, and 12) ring atoms (i.e., 3 to 12-membered heterocyclic groups), wherein 1 to 4 (e.g., 1, 2, 3, and 4) are heteroatoms; more preferably, it comprises 3 to 8 ring atoms (e.g., 3, 4, 5, 6, 7, and 8) (i.e., 3 to 8-membered heterocyclic groups), wherein 1 to 3 are heteroatoms (e.g., 1, 2, and 3); even more preferably, it comprises 3 to 6 ring atoms (i.e., 3 to 6-membered heterocyclic groups), wherein 1 to 3 are heteroatoms; most preferably, it comprises 5 or 6 ring atoms (i.e., 5 or 6-membered heterocyclic groups), wherein 1 to 3 are heteroatoms. Non-limiting examples of monocyclic heterocyclic groups include pyrrolidinyl, tetrahydropyranyl, 1,2,3,6-tetrahydropyridyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, homopiperazinyl, etc. Polycyclic heterocyclic groups include spirocyclic heterocyclic groups, fused heterocyclic groups, and bridged heterocyclic groups.

[0165] The term "spiroheterocyclic group" refers to a 5- to 20-membered polycyclic heterocyclic group in which one or more ring atoms share a single atom (called a spiro atom), wherein the sulfur may be optionally oxidized (i.e., forming a sulfoxide or sulfone), and the remaining ring atoms are carbon. It may contain one or more double bonds. Preferably, it is 6- to 14-membered (i.e., 6- to 14-membered spiroheterocyclic group), more preferably 7- to 10-membered (e.g., 7, 8, 9, or 10-membered) (i.e., 7- to 10-membered spiroheterocyclic group). Spiroheterocyclic groups are classified into monospirocyclic, bispirocyclic, or multispirocyclic groups according to the number of shared spiro atoms between rings, with monospirocyclic and bispirocyclic groups being preferred. More preferably, it is a 4-membered / 4-membered, 4-membered / 5-membered, 4-membered / 6-membered, 5-membered / 5-membered, 5-membered / 6-membered, or 6-membered / 6-membered monospirocyclic group. Non-limiting examples of spiroheterocyclic groups include:

[0166]

[0167] The term "fused heterocyclic group" refers to a 5- to 20-membered polycyclic heterocyclic group in which each ring in the system shares an adjacent pair of atoms with other rings in the system. One or more rings may contain one or more double bonds, wherein one or more ring atoms are heteroatoms selected from nitrogen, oxygen, and sulfur, wherein the sulfur may optionally be oxidized (i.e., forming sulfoxide or sulfone), and the remaining ring atoms are carbon. Preferably, it is a 6- to 14-membered (i.e., a 6- to 14-membered fused heterocyclic group), more preferably a 7- to 10-membered (e.g., 7, 8, 9, or 10-membered) (i.e., a 7- to 10-membered fused heterocyclic group). Depending on the number of constituent rings, it can be classified as a bicyclic, tricyclic, tetracyclic, or polycyclic fused heterocyclic group, preferably bicyclic or tricyclic, more preferably 3-membered / 4-membered, 3-membered / 5-membered, 3-membered / 6-membered, 4-membered / 4-membered, 4-membered / 5-membered, 4-membered / 6-membered, 5-membered / 4-membered, 5-membered / 5-membered, 5-membered / 6-membered, 6-membered / 3-membered, 6-membered / 4-membered, 6-membered / 5-membered, and 6-membered / 6-membered bicyclic fused heterocyclic groups. Non-limiting examples of fused cyclic groups include:

[0168]

[0169] The term "bridged heterocyclic group" refers to a 5- to 14-membered polycyclic heterocyclic group in which any two rings share two non-directly connected atoms. It may contain one or more double bonds, wherein one or more ring atoms are heteroatoms selected from nitrogen, oxygen, and sulfur, wherein the sulfur may optionally be oxidized (i.e., forming sulfoxide or sulfone), and the remaining ring atoms are carbon. Preferably, it is a 6- to 14-membered (i.e., a 6- to 14-membered bridged heterocyclic group), more preferably a 7- to 10-membered (e.g., 7, 8, 9, or 10-membered) (i.e., a 7- to 10-membered bridged heterocyclic group). Depending on the number of constituent rings, it can be classified as a bicyclic, tricyclic, tetracyclic, or polycyclic bridged heterocyclic group, preferably bicyclic, tricyclic, or tetracyclic, more preferably bicyclic or tricyclic. Non-limiting examples of bridged heterocyclic groups include:

[0170]

[0171] The heterocyclic ring comprises a heterocyclic group (including monocyclic heterocyclic groups, spirocyclic groups, fused heterocyclic groups, and bridged heterocyclic groups) fused to an aryl, heteroaryl, or cycloalkyl ring as described above, wherein the ring connected to the parent structure is a heterocyclic group, and non-limiting examples include:

[0172] wait.

[0173] The heterocyclic group can be substituted or unsubstituted. When substituted, it can be substituted at any usable connection point. The substituent is preferably selected from one or more of halogen, alkyl, alkoxy, haloalkyl, haloalkoxy, cycloalkyloxy, heterocyclic oxy, hydroxy, hydroxyalkyl, cyano, amino, nitro, cycloalkyl, heterocyclic, aryl, and heteroaryl.

[0174] The term "aryl" refers to a 6- to 14-membered all-carbon monocyclic or fused polycyclic (fused polycyclic is a ring sharing adjacent carbon atom pairs) group having a conjugated π-electron system, preferably 6- to 10-membered (i.e., 6- to 10-membered aryl), such as phenyl and naphthyl. The aryl ring comprises an aryl ring fused to a heteroaryl, heterocyclic, or cycloalkyl ring as described above, wherein the ring connected to the parent structure is an aryl ring, and non-limiting examples include:

[0175]

[0176] The aryl group can be substituted or unsubstituted. When substituted, it can be substituted at any usable connection point. The substituent is preferably selected from one or more of halogen, alkyl, alkoxy, haloalkyl, haloalkoxy, cycloalkyloxy, heterocyclic oxy, hydroxy, hydroxyalkyl, cyano, amino, nitro, cycloalkyl, heterocyclic, aryl, and heteroaryl.

[0177] The term "heteroaryl" refers to a heteroaryl system comprising 1 to 4 heteroatoms (e.g., 1, 2, 3, and 4) and 5 to 14 ring atoms, wherein the heteroatoms are selected from oxygen, sulfur, and nitrogen. The heteroaryl is preferably 5 to 10-membered (e.g., 5, 6, 7, 8, 9, or 10-membered) (i.e., 5 to 10-membered heteroaryl), more preferably 5 or 6-membered (i.e., 5 or 6-membered heteroaryl), such as furanyl, thiophene, pyridinyl, pyrroleyl, N-alkylpyrroleyl, pyrimidinyl, pyrazinyl, pyridazinyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, etc. The heteroaryl ring comprises a heteroaryl ring fused to an aryl, heterocyclic, or cycloalkyl ring as described above, wherein the ring connected to the parent structure is a heteroaryl ring, and non-limiting examples include:

[0178]

[0179]

[0180] The heteroaryl group can be substituted or unsubstituted. When substituted, it can be substituted at any usable connection point. The substituent is preferably selected from one or more of halogen, alkyl, alkoxy, haloalkyl, haloalkoxy, cycloalkyloxy, heterocyclic oxy, hydroxy, hydroxyalkyl, cyano, amino, nitro, cycloalkyl, heterocyclic, aryl, and heteroaryl.

[0181] The aforementioned cycloalkyl, heterocyclic, aryl, and heteroaryl residues include residues derived from removing one hydrogen atom from a parent ring atom, or residues derived from removing two hydrogen atoms from the same ring atom or two different ring atoms of the parent, namely "divalent cycloalkyl", "divalent heterocyclic", "aryl", and "heteroaryl".

[0182] The term "amino protecting group" is a readily removable group introduced to ensure that the amino group remains unchanged during reactions at other sites of the molecule. Non-limiting examples include (trimethylsilyl)ethoxymethyl, tetrahydropyranyl, tert-butoxycarbonyl, acetyl, benzyl, allyl, and p-methoxybenzyl. These groups may optionally be substituted with 1-3 substituents selected from halogens, alkoxy groups, and nitro groups.

[0183] The term "hydroxyl protecting group" refers to a hydroxyl derivative that is typically used to block or protect the hydroxyl group in a reaction on other functional groups of a compound. Preferably, the hydroxyl protecting group can be triethylsilyl, triisopropylsilyl, tert-butyldimethylsilyl (TBS), tert-butyldiphenylsilyl, methyl, tert-butyl, allyl, benzyl, methoxymethyl (MOM), ethoxyethyl, 2-tetrahydropyranyl (THP), formyl, acetyl, benzoyl, p-nitrobenzoyl, etc.

[0184] The term “cycloalkyloxy” refers to cycloalkyl-O-, where the cycloalkyl group is as defined above.

[0185] The term “heterocyclic oxy group” refers to the heterocyclic group -O-, where the heterocyclic group is as defined above.

[0186] The term "aryloxy group" refers to aryl-O-, where the aryl group is as defined above.

[0187] The term “heteroaryloxy” refers to heteroaryl-O-, where the heteroaryl group is as defined above.

[0188] The term "alkylthio" refers to alkyl-S-, where the alkyl group is as defined above.

[0189] The term "halogenated alkyl" refers to an alkyl group that has been substituted with one or more halogens, wherein the alkyl group is as defined above.

[0190] The term "haloalkoxy" refers to an alkoxy group that is substituted by one or more halogens, wherein the alkoxy group is as defined above.

[0191] The term “deuterated alkyl” refers to an alkyl group that is replaced by one or more deuterium atoms, wherein the alkyl group is as defined above.

[0192] The term "hydroxyalkyl" refers to an alkyl group that is replaced by one or more hydroxyl groups, wherein the alkyl group is as defined above.

[0193] The term "halogen" refers to fluorine, chlorine, bromine, or iodine.

[0194] The term "hydroxyl group" refers to -OH.

[0195] The term "thiol" refers to -SH.

[0196] The term "amino" refers to -NH2.

[0197] The term "cyano" refers to -CN.

[0198] The term "nitro" refers to -NO2.

[0199] The term "oxo" or "oxo" refers to "=O".

[0200] The term "carbonyl" refers to C=O.

[0201] The term "carboxyl group" refers to -C(O)OH.

[0202] The term "carboxylic acid ester group" refers to -C(O)O(alkyl), -C(O)O(cycloalkyl), (alkyl)C(O)O- or (cycloalkyl)C(O)O-, where alkyl and cycloalkyl are as defined above.

[0203] The compounds disclosed herein can exist in specific stereoisomer forms. The term "stereoisomer" refers to isomers with the same structure but different spatial arrangements of atoms. These include cis and trans (or Z and E) isomers, (-)- and (+)- isomers, (R)- and (S)- enantiomers, diastereomers, (D)- and (L)- isomers, tautomers, blocked isomers, conformational isomers, and mixtures thereof (such as racemic mixtures and mixtures of diastereomers). Substituents in the compounds disclosed herein may contain additional asymmetric atoms. All such stereoisomers and mixtures thereof are included within the scope of this disclosure. Optically active (-)- and (+)- isomers, (R)- and (S)- enantiomers, and (D)- and (L)- isomers can be prepared by chiral synthesis, chiral reagents, or other conventional techniques. This disclosure discloses an isomer of a compound, which can be prepared by asymmetric synthesis or with chiral auxiliaries, or, when the molecule contains a basic functional group (such as an amino group) or an acidic functional group (such as a carboxyl group), by forming a salt of the diastereomer with a suitable optically active acid or base, followed by diastereomer resolution using conventional methods known in the art to obtain the pure isomer. Furthermore, the separation of enantiomers and diastereomers is typically performed by chromatography.

[0204] In the chemical structure of the compounds described in this disclosure, the bonds... This indicates that the configuration is not specified; that is, if chiral isomers exist in the chemical structure, the bond... It can be or Or simultaneously include and Two configurations.

[0205] The compounds disclosed herein can exist in various tautomer forms, and all such forms are included within the scope of this disclosure. The terms "tautomer" or "tautomer form" refer to a structural isomer that exists in equilibrium and readily transforms from one isomer to another. This includes all possible tautomers, i.e., existing as a single isomer or as a mixture of said tautomers in any proportion. Non-limiting examples include: keto-enols, imine-enamines, lactam-lactamimides, etc. An example of a lactam-lactamimide in equilibrium is shown below:

[0206]

[0207] When referring to the pyrazolyl group, it should be understood to include any one or a mixture of two tautomers of the following two structures:

[0208]

[0209] All tautomers are within the scope of this disclosure, and the naming of compounds does not exclude any tautomers.

[0210] The compounds disclosed herein include all suitable isotopic derivatives thereof. The term "isotopic derivative" refers to a compound in which at least one atom is replaced by an atom having the same atomic number but a different atomic mass. Examples of isotopes that may be introduced into the compounds of this disclosure include stable and radioactive isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine, chlorine, bromine, and iodine, for example, […]. 2 H (deuterium, D) 3 H (tritium, T) 11 C 13 C 14 C 15 N、 17 O、 18 O、 32 p、 33 p、 33 S, 34 S, 35 S, 36 S, 18 F, 36 Cl、 82 Br、 123 I, 124 I, 125 I, 129 I and 131 Grade I, with deuterium as the preferred grade.

[0211] Compared to undeuterated drugs, deuterated drugs offer advantages such as reduced toxicity, increased drug stability, enhanced efficacy, and prolonged biological half-life. All isotopic variations of the compounds disclosed herein, regardless of radioactivity, are included within the scope of this disclosure. Each available hydrogen atom bonded to a carbon atom can be independently replaced by a deuterium atom, wherein the deuterium substitution can be partial or complete; partial deuterium substitution refers to the replacement of at least one hydrogen atom with at least one deuterium atom.

[0212] In the compounds disclosed herein, when a position is specifically designated as "deuterium" or "D", that position should be understood to indicate that the abundance of deuterium is at least 1000 times greater than the native abundance of deuterium (which is 0.015%) (i.e., at least 15% deuterium doping). In some embodiments, the abundance of deuterium per designated deuterium atom is at least 1000 times greater than the native abundance of deuterium (i.e., at least 15% deuterium doping). In some embodiments, the abundance of deuterium per designated deuterium atom is at least 2000 times greater than the native abundance of deuterium (i.e., at least 30% deuterium doping). In some embodiments, the abundance of deuterium per designated deuterium atom is at least 3000 times greater than the native abundance of deuterium (i.e., at least 45% deuterium doping). In some embodiments, the deuterium abundance of each designated deuterium atom is at least 3340 times greater than the natural deuterium abundance (i.e., at least 50.1% deuterium doping). In some embodiments, the deuterium abundance of each designated deuterium atom is at least 3500 times greater than the natural deuterium abundance (i.e., at least 52.5% deuterium doping). In some embodiments, the deuterium abundance of each designated deuterium atom is at least 4000 times greater than the natural deuterium abundance (i.e., at least 60% deuterium doping). In some embodiments, the deuterium abundance of each designated deuterium atom is at least 4500 times greater than the natural deuterium abundance (i.e., at least 67.5% deuterium doping). In some embodiments, the deuterium abundance of each designated deuterium atom is at least 5000 times greater than the natural deuterium abundance (i.e., at least 75% deuterium doping). In some embodiments, the deuterium abundance of each designated deuterium atom is at least 5500 times greater than the natural deuterium abundance (i.e., at least 82.5% deuterium doping). In some embodiments, the deuterium abundance of each designated deuterium atom is at least 6000 times greater than the natural deuterium abundance (i.e., at least 90% deuterium doping). In some embodiments, the deuterium abundance of each designated deuterium atom is at least 6333.3 times greater than the natural deuterium abundance (i.e., at least 95% deuterium doping). In some embodiments, the deuterium abundance of each designated deuterium atom is at least 6466.7 times greater than the natural deuterium abundance (i.e., at least 97% deuterium doping). In some embodiments, the deuterium abundance of each designated deuterium atom is at least 6600 times greater than the natural deuterium abundance (i.e., at least 99% deuterium doping). In some implementations, the abundance of deuterium in each designated deuterium atom is at least 6633.3 times greater than the natural abundance of deuterium (i.e., at least 99.5% deuterium doping).

[0213] "Optional" or "optional" means that the event or environment described below may but does not have to occur, and the description includes the possibility or absence of the event or environment. For example, "optionally (optionally) alkyl group substituted with halogen or cyano" means that halogen or cyano group may but does not have to be present, and the description includes cases where the alkyl group is substituted with halogen or cyano group and cases where the alkyl group is not substituted with halogen or cyano group.

[0214] "Substituted" refers to one or more hydrogen atoms in a group, preferably 1 to 5, more preferably 1 to 3 hydrogen atoms, which are independently substituted by the corresponding number of substituents. Those skilled in the art can determine possible or impossible substitutions without much effort (through experimentation or theory). For example, an amino or hydroxyl group with free hydrogen may be unstable when combined with a carbon atom having an unsaturated bond (such as an alkene).

[0215] "Pharmaceutical composition" means a mixture containing one or more of the compounds described herein or their pharmaceutically acceptable salts or prodrugs, along with other chemical components, such as pharmaceutically acceptable carriers and excipients. The purpose of a pharmaceutical composition is to facilitate administration to a living organism, thereby promoting the absorption of the active ingredient and its biological activity.

[0216] "Pharmacologically acceptable salt" refers to the salt of the compounds disclosed herein, which may be selected from inorganic or organic salts. Such salts are safe and effective when used in mammals and possess the expected biological activity. The salt can be prepared separately during the final isolation and purification of the compound, or by reacting a suitable group with a suitable base or acid. Bases commonly used to form pharmaceutically acceptable salts include inorganic bases, such as sodium hydroxide and potassium hydroxide, and organic bases, such as ammonia. Acids commonly used to form pharmaceutically acceptable salts include both inorganic and organic acids.

[0217] For the purposes of pharmaceuticals or pharmacologically active agents, the term "therapeutic effective amount" refers to the amount of a drug or agent sufficient to achieve or at least partially achieve the intended effect. The determination of the therapeutic effective amount varies from person to person, depending on the recipient's age and general condition, as well as the specific active substance. The appropriate therapeutic effective amount in a given case can be determined by a person skilled in the art based on routine testing.

[0218] As used herein, the term "pharmaceutically acceptable" means that these compounds, materials, compositions, and / or dosage forms are suitable for contact with patient tissues without excessive toxicity, irritation, allergic reactions, or other problems or complications, within reasonable medical judgment, have a reasonable benefit / risk ratio, and are effective for their intended use.

[0219] As used herein, the singular forms of “a,” “an,” and “the” include plural references, and vice versa, unless the context clearly indicates otherwise.

[0220] When the term "about" is applied to parameters such as pH, concentration, temperature, etc., it indicates that the parameter can vary by ±10%, and sometimes more preferably within ±5%. As those skilled in the art will understand, when a parameter is not critical, figures are usually given for illustrative purposes only, not as limitations.

[0221] The method for synthesizing the compounds disclosed herein

[0222] In order to achieve the purpose of this disclosure, the following technical solution is adopted:

[0223] Option 1

[0224] This disclosure discloses a method for preparing a compound of formula (IM) or a pharmaceutically acceptable salt thereof, the method comprising the following steps:

[0225]

[0226] A compound of general formula (IMa) or a salt thereof (preferably a hydrochloride salt) undergoes a nucleophilic substitution reaction with a compound of general formula (IIMb) under basic conditions, optionally in the presence of a catalyst, to give a compound of general formula (IM) or a pharmaceutically usable salt thereof.

[0227] in:

[0228] L is a halogen, preferably a chlorine atom;

[0229] G 1 G 2 G 3 Ring A, Ring B, R 0 R 1 R 2 R 3 , s, t, m and n are as defined in the general formula (IM).

[0230] Option 2

[0231] The present disclosure discloses a method for preparing the compound of formula (I) or a pharmaceutically acceptable salt thereof, the method comprising the following steps:

[0232]

[0233] A compound of general formula (IMa) or a salt thereof (preferably a hydrochloride salt) undergoes a nucleophilic substitution reaction with a compound of general formula (IIb) under basic conditions, optionally in the presence of a catalyst, to give a compound of general formula (I) or a pharmaceutically usable salt thereof.

[0234] in:

[0235] L is a halogen, preferably a chlorine atom;

[0236] G1 G 2 G 3 Ring A, Ring B, R 1 R 2 R 3 , s, t, m and n are as defined in general formula (I).

[0237] Option 3

[0238] This disclosure discloses a method for preparing a compound of formula (IIM) or a pharmaceutically acceptable salt thereof, the method comprising the following steps:

[0239]

[0240] A compound of general formula (IIMa) or a salt thereof (preferably a hydrochloride salt) undergoes a nucleophilic substitution reaction with a compound of general formula (IIMb) under basic conditions, optionally in the presence of a catalyst, to give a compound of general formula (IIM) or a pharmaceutically usable salt thereof.

[0241] in:

[0242] L is a halogen, preferably a chlorine atom;

[0243] G 1 G 2 G 3 X, Y, ring B, R 0 R 1 R 3 , t and n are as defined in the general formula (IIM).

[0244] Option 4

[0245] The present disclosure discloses a method for preparing the compound of formula (II) or a pharmaceutically acceptable salt thereof, the method comprising the following steps:

[0246]

[0247] A compound of general formula (IIMa) or a salt thereof (preferably a hydrochloride salt) undergoes a nucleophilic substitution reaction with a compound of general formula (IIb) under basic conditions, optionally in the presence of a catalyst, to give a compound of general formula (II) or a pharmaceutically usable salt thereof.

[0248] in:

[0249] L is a halogen, preferably a chlorine atom;

[0250] G 1 G 2 G 3 X, Y, ring B, R 1 R 3 , t and n are as defined in general formula (II).

[0251] Option 5

[0252] A method for preparing the compound of formula (III) or a pharmaceutically acceptable salt thereof, comprising the following steps:

[0253]

[0254] A compound of general formula (IIIa) or a salt thereof (preferably a hydrochloride salt) undergoes a nucleophilic substitution reaction with a compound of general formula (V) under basic conditions, optionally in the presence of a catalyst, to give a compound of general formula (III) or a pharmaceutically usable salt thereof.

[0255] in:

[0256] L is a halogen, preferably a chlorine atom;

[0257] X, Y, R 1 R 7a R 7b And n is as defined in general formula (III).

[0258] The alkalis include organic alkalis and inorganic alkalis. The organic alkalis include, but are not limited to, triethylamine, N,N-diisopropylethylamine, n-butyllithium, diisopropylaminolithium, sodium acetate, potassium acetate, sodium ethoxide, sodium tert-butoxide, and potassium tert-butoxide, with N,N-diisopropylethylamine being preferred. The inorganic alkalis include, but are not limited to, sodium hydride, potassium phosphate, sodium carbonate, potassium carbonate, cesium carbonate, sodium hydroxide, lithium hydroxide monohydrate, lithium hydroxide, and potassium hydroxide.

[0259] The catalyst for the above nucleophilic substitution reaction is sodium iodide or potassium iodide, preferably sodium iodide.

[0260] The above reaction is preferably carried out in a solvent, which includes, but is not limited to: N-methylpyrrolidone, ethylene glycol dimethyl ether, acetic acid, methanol, ethanol, acetonitrile, n-butanol, toluene, tetrahydrofuran, dichloromethane, petroleum ether, ethyl acetate, n-hexane, dimethyl sulfoxide, 1,4-dioxane, water, N,N-dimethylformamide, N,N-dimethylacetamide, 1,2-dibromoethane, and mixtures thereof. Detailed Implementation

[0261] The following embodiments are used to further describe this disclosure, but these embodiments are not intended to limit the scope of this disclosure.

[0262] Example

[0263] The structure of the compound was determined by nuclear magnetic resonance (NMR) and / or mass spectrometry (MS). NMR shifts (δ) were expressed in 10⁻¹⁰. -6The unit (ppm) is given. NMR determination was performed using a Bruker AVANCE-400 NMR spectrometer or a Bruker AVANCE NEO 500M. The solvents used were deuterated dimethyl sulfoxide (DMSO-d6), deuterated chloroform (CDCl3), and deuterated methanol (CD3OD). The internal standard was tetramethylsilane (TMS).

[0264] MS measurements were performed using an Agilent 1200 / 1290DAD-6110 / 6120 Quadrupole MS liquid chromatography-mass spectrometry system (manufacturer: Agilent, MS model: 6110 / 6120 Quadrupole MS).

[0265] waters ACQuity UPLC-QD / SQD (Manufacturer: waters, MS model: waters ACQuity QdaDetector / waters SQ Detector) THERMO Ultimate 3000-Q Exactive (Manufacturer: THERMO, MS model: THERMO Q Exactive).

[0266] High-performance liquid chromatography (HPLC) analysis was performed using an Agilent HPLC 1200DAD, an Agilent HPLC 1200VWD, and a Waters HPLC e2695-2489 liquid chromatograph.

[0267] Chiral HPLC analysis was performed using an Agilent 1260DAD high-performance liquid chromatograph.

[0268] High performance liquid chromatography (HPLC) was performed using Waters 2545-2767, Waters 2767-SQ Detecor2, Shimadzu LC-20AP, and Gilson GX-281 preparative chromatographs.

[0269] Chiral preparation was performed using a Shimadzu LC-20AP preparative chromatograph.

[0270] The CombiFlash rapid preparation system uses a CombiFlash Rf200 (TELEDYNE ISCO).

[0271] Thin-layer chromatography silica gel plates are Yantai Huanghai HSGF254 or Qingdao GF254. The silica gel plates used in thin-layer chromatography (TLC) have a diameter of 0.15 mm to 0.2 mm, and the diameter of the silica gel plates used for thin-layer chromatography separation and purification products is 0.4 mm to 0.5 mm.

[0272] Silica gel column chromatography generally uses Yantai Huanghai silica gel with a mesh size of 200-300 as the carrier.

[0273] Mean inhibition rate of kinases and IC 50 The values ​​were determined using a NovoStar microplate reader (BMG GmbH, Germany).

[0274] The known starting materials disclosed herein can be synthesized using or in accordance with methods known in the art, or can be purchased from companies such as ABCR GmbH & Co. KG, Acros Organics, Aldrich Chemical Company, AccelaChemBio Inc, and Darui Chemicals.

[0275] Unless otherwise specified in the examples, the reactions can be carried out under an argon or nitrogen atmosphere.

[0276] Argon or nitrogen atmosphere refers to a reaction flask connected to an argon or nitrogen gas balloon with a volume of approximately 1L.

[0277] A hydrogen atmosphere refers to a reaction flask connected to a hydrogen balloon with a volume of approximately 1L.

[0278] The pressurized hydrogenation reaction was performed using a Parr 3916EKX hydrogenator and a Qinglan QL-500 hydrogen generator or an HC2-SS hydrogenator.

[0279] The hydrogenation reaction is usually carried out under vacuum, filled with hydrogen gas, and repeated 3 times.

[0280] The microwave reaction was performed using a CEM Discover-S 908860 microwave reactor.

[0281] Unless otherwise specified in the examples, "solution" refers to an aqueous solution.

[0282] Unless otherwise specified in the examples, the reaction temperature is room temperature, which is 20℃~30℃.

[0283] The reaction process in the examples was monitored using thin-layer chromatography (TLC). The developing solvent used in the reaction, the eluent system for column chromatography used to purify the compounds, and the developing solvent system for TLC included: A: dichloromethane / methanol system. The volume ratio of the solvent was adjusted according to the polarity of the compounds. Small amounts of basic or acidic reagents such as triethylamine and acetic acid could also be added for adjustment.

[0284] Example 1

[0285] 5-(5-((7-ethyl-6-oxo-5,6-dihydro-1,5-naphthid-3-yl)methyl)-5,6-dihydropyrrolo[3,4-c]pyrazole

[0286] -2(4H)-yl)-N-methylpyridinecarboxamide 1

[0287]

[0288] first step

[0289] 2-(6-(methoxycarbonyl)pyridin-3-yl)-2,6-dihydropyrrolo[3,4-c]pyrazole-5(4H)-carboxylic acid tert-butyl ester 1c

[0290] 5-Bromopyridine-2-carboxylic acid methyl ester 1b (200 mg, 925.78 μmol, Shanghai Shaoyuan), 2,6-dihydro-1H-pyrrolo[3,4-c]pyrazole-5(4H)-carboxylic acid butyl ester 1a (290 mg, 1.38 mmol, Shanghai Bide) were dissolved in 1,4-dioxane (5 mL), and cuprous iodide (35 mg, 183.77 μmol), (1S,2S)-(+)-1,2-cyclohexanediamine (21 mg, 183.90 μmol), and cesium carbonate (301 mg, 923.82 μmol) were added. Under nitrogen protection, the mixture was heated to 120 °C and stirred for 14 hours. The reaction solution was cooled to room temperature, filtered through diatomaceous earth, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography using eluent system A to give the title compound 1c (205 mg, yield: 64.3%).

[0291] MS m / z(ESI): 345.2 [M+1].

[0292] Step 2

[0293] 2-(6-(methylaminocarbonyl)pyridin-3-yl)-2,6-dihydropyrrolo[3,4-c]pyrazole-5(4H)-carboxylic acid tert-butyl ester 1d

[0294] Compound 1c (200 mg, 580.8 μmol) was dissolved in 15 mL of 1 M methylamine in ethanol, and the mixture was stirred for 48 hours. The reaction solution was concentrated under reduced pressure to obtain crude title compound 1d (190 mg, yield: 95.2%). The product was directly used for the next reaction without purification.

[0295] MS m / z(ESI): 344.2 [M+1].

[0296] Step 3

[0297] 5-(5,6-dihydropyrrolo[3,4-c]pyrazole-2(4H)-yl)-N-methylpyridinecarboxamide hydrochloride 1e

[0298] The crude compound 1d (140 mg, 407.7 μmol) was dissolved in dichloromethane (2 mL), and 1 mL of 4 M dioxane hydrochloride solution was added. The mixture was stirred for 0.5 hours. The reaction solution was concentrated under reduced pressure to obtain the crude title compound 1e (110 mg, yield: 96.5%). The product was used directly in the next step of the reaction without purification.

[0299] MS m / z(ESI):245.2[M+1].

[0300] Step 4

[0301] 5-(5-((7-ethyl-6-oxo-5,6-dihydro-1,5-naphthid-3-yl)methyl)-5,6-dihydropyrrolo[3,4-c]pyrazol-2(4H)-yl)-N-methylpyridinecarboxamide 1

[0302] The crude compound 1e (30 mg, 134.7 μmol), compound 7-(chloromethyl)-3-ethyl-1,5-naphthidium-2(1H)-one 1f (37 mg, 132.2 μmol, prepared by the method disclosed in Example 4 on page 15 of patent application "WO2021013735A1"), N,N-diisopropylethylamine (174 mg, 1.34 mmol), and sodium iodide (2.7 mg, 11.96 μmol) were dissolved in acetonitrile (3 mL). The mixture was reacted at 80 °C for 5 hours. After the reaction solution was concentrated under reduced pressure, the crude product was subjected to high performance liquid chromatography (Waters-2545, column: SharpSil-T) for 5 hours. C18, 30*150mm, 5μm; mobile phase: aqueous phase (10mmol / L ammonium bicarbonate) and acetonitrile, gradient ratio: acetonitrile 35%-45%, flow rate: 30mL / min) to obtain title compound 1 (6mg, yield: 6.8%).

[0303] MS m / z(ESI): 430.2 [M+1].

[0304] 1 H NMR (500MHz, CD3OD): δ9.05(d,1H),8.56(d,1H),8.24(dd,1H),8.15(d,1H),8.11-8.04(m,1H),7 .83(d,2H),4.19(d,2H),3.92(t,2H),3.35(s,2H),2.97(d,3H),2.68(q,3H),1.32-1.26(m,2H).

[0305] Example 2

[0306] 5-(5-((7-ethyl-6-oxo-5,6-dihydro-1,5-naphthid-3-yl)methyl)-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridin-2-yl)-N-methylpyridinecarboxamide 2-P1

[0307] 5-(5-((7-ethyl-6-oxo-5,6-dihydro-1,5-naphthid-3-yl)methyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)-N-methylpyridinecarboxamide 2-P2

[0308]

[0309]

[0310] first step

[0311] 2-(6-(methoxycarbonyl)pyridin-3-yl)-2,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxylic acid tert-butyl ester 2b-P1

[0312] 1-(6-(methoxycarbonyl)pyridin-3-yl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxylic acid tert-butyl ester 2b-P2

[0313] Compound 2,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxylic acid tert-butyl ester 2a (300 mg, 1.34 mmol, Shanghai Bide) was dissolved in N,N-dimethylformamide (5 mL), sodium hydride (102 mg, 2.66 mmol, 60% purity) was added, and the mixture was stirred for 30 minutes. Then, compound 1b (229 mg, 1.47 mmol) was added, and the mixture was heated to 40 °C and reacted for 3 hours. The reaction was quenched with water, extracted with dichloromethane (10 mL × 3), and the organic phases were combined. The mixture was dried over anhydrous sodium sulfate, filtered to remove the desiccant, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography with eluent system A to give a mixture of title compounds 2b-P1 and 2b-P2 (100 mg, yield 20.7%).

[0314] MS m / z(ESI): 359.2 [M+1].

[0315] The synthetic route in Example 1 was then used, with the starting material 1c in the second step replaced by a mixture of compounds 2b-P1 and 2b-P2, to obtain the title compound (10 mg, 40 mg, yield: 8.36%, 33.4%).

[0316] Single configuration compound (shorter retention time, 10 mg, yield: 8.36%)

[0317] MS m / z(ESI):444.2[M+1].

[0318] HPLC analysis: Retention time: 0.91 min, Purity: 97% (Column: ACQUITY) BEH, C18, 1.7 μm, 2.1*50 mm; Mobile phase: water (10 mM ammonium bicarbonate), acetonitrile, gradient ratio: acetonitrile 10%-95%. ¹H NMR (500 MHz, CD₃OD): δ 8.90 (dd, ¹H), 8.53 (d, ¹H), 8.20 (dd, ¹H), 8.14 (dd, ¹H), 7.84 (q, ¹H), 7.83-7.79 (m, ¹H), 7.58 (s, ¹H), 3.93 (s, 2H), 3.64 (s, 2H), 2.99 (d⁵H), 2.90 (t, 2H), 2.67 (dd, 2H), 1.29 (s, 3H).

[0319] Single configuration compound (longer retention time, 40 mg, yield: 33.4%)

[0320] MS m / z(ESI):444.2[M+1].

[0321] HPLC analysis: Retention time 0.96 min, purity: 98% (Column: ACQUITY) BEH, C18, 1.7 μm, 2.1*50 mm; Mobile phase: water (10 mM ammonium bicarbonate), acetonitrile, gradient ratio: acetonitrile 10%-95%. ¹H NMR (500 MHz, CD₃OD): δ 9.05 (d, 1H), 8.54 (d, 1H), 8.24 (dd, 1H), 8.17 (d, 1H), 8.13 (s, 1H), 7.86 (d, 1H), 7.82 (d, 1H), 3.94 (s, 2H), 3.69 (s, 2H), 3.00-2.89 (m, 7H), 2.69 (qd, 2H), 1.30 (d, 3H).

[0322] Example 3

[0323] 5-(5-((7-ethyl-6-oxo-5,6-dihydro-1,5-naphthid-3-yl)methyl)-3-methyl-5,6-dihydropyrrolo[3,4-c]pyrazol-2(4H)-yl)-N-methylpyridinecarboxamide 3-P1

[0324] 5-(5-((7-ethyl-6-oxo-5,6-dihydro-1,5-naphthid-3-yl)methyl)-3-methyl-5,6-dihydropyrrolo[3,4-c]pyrazol-1(4H)-yl)-N-methylpyridinecarboxamide 3-P2

[0325]

[0326] first step

[0327] 2-(6-(methoxycarbonyl)pyridin-3-yl)-3-methyl-2,6-dihydropyrrolo[3,4-c]pyrazole-5(4H)-carboxylic acid tert-butyl ester

[0328] 3b-P1

[0329] 1-(6-(methoxycarbonyl)pyridin-3-yl)-3-methyl-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxylic acid tert-butyl ester

[0330] 3b-P2

[0331] Compound 3-methyl-2,6-dihydropyrrolo[3,4-c]pyrazole-5(4H)-carboxylic acid tert-butyl ester 3a (200 mg, 895.77 μmol, Nanjing Pharmaceutical) was dissolved in N,N-dimethylformamide (3 mL), sodium hydride (68 mg, 1.77 mmol, 60% purity) was added, and the mixture was stirred for 30 minutes. Then, compound 1b (152 mg, 979.84 μmol) was added, and the mixture was heated to 40 °C and reacted for 3 hours. The reaction was quenched with water, extracted with dichloromethane (10 mL × 3), and the organic phases were combined. The mixture was dried over anhydrous sodium sulfate, filtered to remove the desiccant, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography with eluent system A to give a mixture of title compounds 3b-P1 and 3b-P2 (300 mg, yield 93.4%).

[0332] MS m / z(ESI): 359.2 [M+1].

[0333] The synthetic route in Example 1 was then used, with the second-step starting material compound 1c replaced by a mixture of compounds 3b-P1 and 3b-P2, to obtain 10 mg of the title compound, with yields of 8.36% and 8.36%.

[0334] Single configuration compound (shorter retention time, 10 mg, yield: 8.36%)

[0335] MS m / z(ESI):444.2[M+1].

[0336] HPLC analysis: Retention time: 0.91 min, Purity: 99% (Column: ACQUITY) BEH, C18, 1.7 μm, 2.1*50 mm; Mobile phase: water (10 mM ammonium bicarbonate), acetonitrile, gradient ratio: acetonitrile 10%-95%. ¹H NMR (500 MHz, CD₃OD): δ 8.77 (d, ¹H), 8.54 (d, ¹H), 8.20 (d, ¹H), 8.06 (dd, ¹H), 7.87-7.74 (m, 2H), 4.14 (s, 2H), 3.87 (s, 2H), 3.82 (s, 2H), 2.97 (s, 3H), 2.66 (qd, 2H), 2.34 (s, 3H), 1.27 (d, 3H).

[0337] Single configuration compound (longer retention time, 10 mg, yield: 8.36%)

[0338] MS m / z(ESI):444.2[M+1].

[0339] HPLC analysis: Retention time 0.92 min, purity: 99% (Column: ACQUITY) BEH, C18, 1.7 μm, 2.1*50 mm; Mobile phase: water (10 mM ammonium bicarbonate), acetonitrile, gradient ratio: acetonitrile 10%-95%. ¹H NMR (500 MHz, CD₃OD): δ 8.87 (d, 1H), 8.56 (s, 1H), 8.13 (d, 2H), 8.02-7.99 (m, 1H), 7.86 (s, 2H), 4.27 (s, 2H), 4.20 (s, 2H), 4.00 (s, 2H), 2.97 (s, 3H), 2.27 (s, 3H), 2.19 (s, 2H), 1.28 (s, 3H).

[0340] Example 4

[0341] 5-(5-((7-ethyl-6-oxo-5,6-dihydro-1,5-naphthid-3-yl)methyl)-3-(hydroxymethyl)-5,6-dihydropyrrolo[3,4-c]pyrazol-2(4H)-yl)-N-methylpyridinecarboxamide 4

[0342]

[0343]

[0344] first step

[0345] 2-(1-Benzyl-4-oxopyrrolidine-3-yl)-2-oxoethyl acetate 4b

[0346] Sodium ethoxide (6.9 g, 101.39 mmol) was dissolved in ethanol (100 mL). Diethyl oxalate (13.7 g, 93.74 mmol) and 10 mL of an ethanol solution of 1-benzyl-3-pyrrolidone 4a (15 g, 85.6035 mmol, Shanghai Shaoyuan) were added under ice bath conditions. The mixture was stirred and reacted at room temperature for 15 hours. The reaction solution was filtered, and the filter cake was dried to obtain the title compound 4b (10 g, yield: 42.4%).

[0347] MS m / z(ESI):276.1[M+1].

[0348] Step 2

[0349] 5-Benzyl-1,4,5,6-Tetrahydropyrrolo[3,4-c]pyrazole-3-carboxylic acid ethyl ester 4c

[0350] Compound 4b (2.1 g, 7.62 mmol) was dissolved in acetic acid (60 mL), and hydrazine hydrate (539.1 mg, 9.15 mmol, 85% purity) was added. The mixture was heated to 110 °C and reacted for 5 hours. The reaction solution was concentrated under reduced pressure and diluted with water. The pH was adjusted to approximately 8 with 2N sodium hydroxide. The mixture was extracted with ethyl acetate (50 mL × 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered to remove the desiccant, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography using eluent system A to give the title compound 4c (800 mg, yield: 38.6%).

[0351] MS m / z(ESI):272.2[M+1].

[0352] Step 3

[0353] (5-Benzyl-1,4,5,6-Tetrahydropyrrolo[3,4-c]pyrazol-3-yl)methanol 4d

[0354] Compound 4c (600 mg, 2.2115 mmol) was dissolved in tetrahydrofuran (20 mL), and 4.4 mL of 1 M lithium aluminum hydride tetrahydrofuran solution was added. The mixture was stirred at 0 °C for 1 hour, and then allowed to return to room temperature for another 15 hours. 0.2 mL of water, 0.2 mL of 15% sodium hydroxide aqueous solution, and 0.4 mL of water were added sequentially to the reaction solution. Anhydrous sodium sulfate was then added and stirred for 10 minutes. The mixture was filtered, and the filtrate was concentrated to obtain the title compound 4d (270 mg, yield: 53.2%). The product was used directly in the next reaction without purification.

[0355] MS m / z(ESI):230.1[M+1].

[0356] Step 4

[0357] 5-Benzyl-3-(((tert-butyldimethylsiloxy)methyl)-2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole 4e

[0358] Compound 4d (380 mg, 1.65 mmol) was dissolved in N,N-dimethylformamide (4 mL), and compound tert-butyldimethylchlorosilane (499 mg, 3.31 mmol) and imidazole (225 mg, 3.30 mmol) were added. The mixture was stirred for 15 hours, and the reaction solution was quenched with water. The mixture was then extracted with ethyl acetate (10 mL × 3). The organic phases were combined, dried with anhydrous sodium sulfate, filtered to remove the desiccant, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography with eluent system A to give the title compound 4e (280 mg, yield: 49.1%).

[0359] MS m / z(ESI): 344.2 [M+1].

[0360] Step 5

[0361] 5-(5-benzyl-3-(((tert-butyldimethylsilyl)oxy)methyl)-5,6-dihydropyrrolo[3,4-c]pyrazole-2(4H)-yl)methyl pyridinecarboxylate 4f

[0362] Compound 4e (270 mg, 785.94 μmol) and methyl 5-bromopyridine-2-carboxylic acid (186.7 mg, 864.22 μmol, Shanghai Shaoyuan) were dissolved in 1,4-dioxane (5 mL). Cuprous iodide (74 mg, 388.55 μmol), N,N'-dimethyl-1,2-cyclohexanediamine (55 mg, 386 μmol), and cesium carbonate (256 mg, 785.7 μmol) were added, and the mixture was heated to 120 °C and reacted for 15 hours. The reaction solution was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography using eluent system A to give the title compound 4f (150 mg, yield: 39.8%).

[0363] MS m / z(ESI):479.2[M+1].

[0364] Step 6

[0365] 5-(5-benzyl-3-(((tert-butyldimethylsilyl)oxy)methyl)-5,6-dihydropyrrolo[3,4-c]pyrazole-2(4H)-

[0366] 4g of 4g of N-methylpyridinecarboxamide

[0367] Compound 4f (150 mg, 411.63 μmol) was dissolved in 5 mL of 1 M methylamine in ethanol and stirred for 15 hours. The reaction solution was concentrated under reduced pressure to obtain crude title compound 4 g (150 mg, yield: 76.2%). The product was directly used for the next reaction without purification.

[0368] MS m / z(ESI):478.2[M+1].

[0369] Step 7

[0370] 5-(3-(hydroxymethyl)-5,6-dihydropyrrolo[3,4-c]pyrazole-2(4H)-yl)-N-methylpyridinecarboxamide 4h

[0371] 4 g (25 mg, 52.3 μmol) of compound 1-chloroethyl chloroformate (29.8 mg, 209.2 μmol, Shanghai Shaoyuan) was dissolved in dichloromethane (5 mL), heated to 40 °C and reacted for 2 hours. The reaction solution was concentrated under reduced pressure, and the residue was dissolved in methanol (5 mL). The reaction solution was heated to 60 °C and reacted for 1 hour. The reaction solution was concentrated under reduced pressure, and the residue was purified by high performance liquid chromatography (Waters-2545, column: SharpSil-T C18, 30*150 mm, 5 μm; mobile phase: aqueous phase (10 mmol / L ammonium bicarbonate) and acetonitrile, gradient ratio: acetonitrile 35%-45%, flow rate: 30 mL / min) to obtain the title compound 4h (5 mg, yield: 34.9%).

[0372] MS m / z(ESI):274.2[M+1].

[0373] Step 8

[0374] 5-(5-((7-ethyl-6-oxo-5,6-dihydro-1,5-naphthid-3-yl)methyl)-3-(hydroxymethyl)-5,6-dihydropyrrolo

[0375] [3,4-c]pyrazole-2(4H)-yl)-N-methylpyridinecarboxamide 4

[0376] Using the synthetic route in Example 1, the starting compound 1e in step 4 was replaced with compound 4h to obtain title compound 4 (3 mg, yield: 48.4%).

[0377] MS m / z(ESI): 460.2 [M+1].

[0378] 1H NMR (500MHz, CD3OD): δ8.90(t,1H),8.56(d,1H),8.20(d,2H),7.85(s,1H),7.82(d,1H),4.60(d,2H),4 .17(s,2H),3.92(d,3H),2.98(s,2H),2.72-2.64(m,2H),2.19(t,2H),2.03(s,1H),1.35-1.26(m,2H).

[0379] Biological evaluation

[0380] The following test examples further describe and explain this disclosure, but these test examples are not intended to limit the scope of this disclosure.

[0381] Test Example 1: Cell Proliferation Experiment

[0382] The following method detects intracellular ATP levels and, based on IC50... 50 Size evaluation of the disclosed compounds on DLD1 cells, DLD1 BRCA2- / - The inhibitory effect on the proliferation of MDA-MB-436 cells was investigated. The experimental methods are briefly described below:

[0383] I. Experimental Materials and Instruments

[0384] 1. DLD1, human colon cancer tumor cells (Nanjing Kebai, CBP60037)

[0385] 2.DLD1 BRCA2- / - Human BRCA2 gene knockout colon cancer cells (Creative biogene, CSC-RT0015)

[0386] 3. MDA-MB-436, human breast cancer cells (ATCC, HTB-130)

[0387] 4. Fetal bovine serum (GIBCO, 10091-148)

[0388] 5. CellTite-Glo reagent (Promega, G7573)

[0389] 6.96-well cell culture plate (corning, 3903)

[0390] 7. Pancreatic enzyme (invitrogen, 25200-072)

[0391] 8. Microplate reader (BMG, Pherasta)

[0392] 9. Cell counter (Shanghai Ruiyu Biotechnology Co., Ltd., IC1000)

[0393] II. Experimental Procedure

[0394] DLD1 cells were cultured in RPMI-1640 medium containing 10% FBS, passaged 2-3 times per week at a passage ratio of 1:6 or 1:8. During passage, cells were digested with trypsin and transferred to centrifuge tubes, centrifuged at 1200 rpm for 3 minutes, the supernatant was discarded, and the cells were resuspended in fresh medium. 180 μL of the cell suspension was added to each 96-well cell culture plate, at a density of 2.78 × 10⁻⁶ cells / well. 3 Cells / mL, add only 180 μL of complete culture medium to the periphery of the 96-well plate.

[0395] DLD1 BRCA2- / - Cells were cultured in RPMI-1640 medium containing 10% FBS, passaged 2-3 times per week at a passage ratio of 1:6 or 1:8. During passage, cells were digested with trypsin and transferred to centrifuge tubes, centrifuged at 1200 rpm for 3 minutes, the supernatant was discarded, and the cells were resuspended in fresh medium. 180 μL of the cell suspension was added to each 96-well cell culture plate, resulting in a density of 8.34 × 10⁻⁶ cells / well. 3 Cells / mL, add only 180 μL of complete culture medium to the periphery of the 96-well plate.

[0396] MDA-MB-436 cells were cultured in Leibovitz's L-15 medium containing 10% FBS, 10 μg / mL insulin, and 16 μg / mL glutathione, and passaged 2–3 times per week at a passage ratio of 1:3 or 1:5. During passage, cells were digested with trypsin and transferred to centrifuge tubes, centrifuged at 1200 rpm for 3 minutes, and the supernatant was discarded. The cells were resuspended in fresh medium. 180 μL of the cell suspension was added to each 96-well cell culture plate, resulting in a density of 8.34 × 10⁻⁶ cells / well. 3 Cells / mL, add only 180 μL of complete culture medium to the periphery of the 96-well plate.

[0397] The culture plates were incubated in an incubator for 24 hours (37°C, 5% CO2).

[0398] The test samples were diluted to 2 mM with DMSO, and then serially diluted 3-fold to obtain 10 concentrations, with blank and control wells provided. 5 μL of the prepared gradient concentration test compound solutions were added to 95 μL of fresh culture medium. Then, 20 μL of the above drug-containing culture medium solution was added to the culture plate. The culture plate was incubated for 6 days (37℃, 5% CO2). In a 96-well cell culture plate, 90 μL of CellTiter-Glo reagent was added to each well, and the plate was incubated at room temperature in the dark for 5–10 min. The chemiluminescence signal values ​​were read using Pherastar, and the data were processed using GraphPad software. The results are shown in Table 1.

[0399] Table 1. The effects of the disclosed compounds on DLD1 and DLD1 BRCA2- / - Inhibitory effect on the proliferation of MDA-MB-436 cells

[0400]

[0401] Conclusion: The disclosed compound is effective against DLD1. BRCA2- / - It has a good inhibitory effect on the proliferation of MDA-MB-436 cells.

[0402] Test Example 2: Determination of the binding activity of the disclosed compounds on PARP1 and PARP2.

[0403] The in vitro PARP1 and PARP2 binding activity was tested using the following methods.

[0404] I. Experimental Materials and Instruments

[0405] 1. PARP1 recombinant protein (Sino Biotech, catalog number 11040-H08B);

[0406] 2. Recombinant PARP2 protein (BPS, catalog number 80502)

[0407] 3. Fluorescent probe (made in-house using a compound with CAS number 1380359-84-1, Shanghai Hengrui);

[0408] 4.384-hole plate (Corning, 3575)

[0409] 5. Pherastar FS microplate reader (BMG Labtech)

[0410] II. Experimental Procedure

[0411] Add 8 μL of binding buffer to each well of a 384-well plate; dissolve the fluorescent probe in dimethyl sulfoxide (DMSO) and dilute to the appropriate concentration. Then, dilute the DMSO-prepared fluorescent probe 20-fold in binding buffer (50 mM Tris-HCl pH 8.0, 50 mM NaCl, 1 mM MgCl2, 0.1 mM EDTA, 0.01% IGEPA), adding 2 μL to each well; dissolve the test compound in DMSO and dilute to various concentration gradients as needed. Then, dilute each concentration of the compound prepared in DMSO 20-fold in binding buffer, adding 2 μL to each well; dilute PARP1 or PARP2 protein to the appropriate concentration using binding buffer, adding 8 μL / well to a black 384-well plate, mixing thoroughly, and incubating at 25°C for 40 minutes. Read the signal values ​​using the FP program in the Pherastar FS microplate reader. Data were processed using GraphPad software.

[0412] The PARP1 and PARP2 binding inhibitory activities of the disclosed compounds were determined by the above experiments, and the measured IC50 values ​​were... 50 The values ​​are shown in Table 2.

[0413] Table 2 shows the inhibitory activity of the compounds disclosed in this study on PARP1 and PARP2 binding.

[0414]

[0415] Conclusion: The compound disclosed herein exhibits selective inhibition of PARP1.

Claims

1. A compound of general formula (IM) or a pharmaceutically acceptable salt thereof: in: Ring A is a pyrazol group; Ring B is pyridinyl; G 1 For CH, G 2 For nitrogen atoms, G 3 For CR 6 ;R 6 It is a hydrogen atom; R 1 C 1-6 alkyl; R 0 It is a hydrogen atom; R 2 Selected from hydrogen atoms, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Haloalkyl, C 1-6 Halogenated alkoxy groups and C 1-6 Hydroxyalkyl; R 3 -C(O)NR 7a R 7b ; R 7a and R 7b They may be the same or different, and each is independently a hydrogen atom or a carbon atom. 1-6 alkyl; m is 1; n is 1 or 2; s is 0 or 1; and t is 1.

2. The compound of formula (IM) according to claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound is of formula (IIM) or a pharmaceutically acceptable salt thereof: in: X is a nitrogen atom and Y is a CR atom. 2 Or X is CR 2 And Y is a nitrogen atom; n is 1 or 2; Rings B and G 1 G 2 G 3 R 0 R 1 R 2 R 3 And t as defined in claim 1.

3. The compound of general formula (IM) according to claim 1, or a pharmaceutically acceptable salt thereof, wherein it is the compound of general formula (III) or a pharmaceutically acceptable salt thereof: in: X is a nitrogen atom and Y is a CR atom. 2 Or X is CR 2 And Y is a nitrogen atom; n is 1 or 2; R 1 R 2 R 7a and R 7b As defined in claim 1.

4. The compound of formula (IM) according to claim 1, or a pharmaceutically acceptable salt thereof, wherein R 1 It is an ethyl group.

5. The compound of formula (IM) according to claim 1, or a pharmaceutically acceptable salt thereof, wherein R 2 Selected from hydrogen atoms, C 1-6 Alkyl and C 1-6 Hydroxyalkyl.

6. The compound of formula (IM) according to claim 1, or a pharmaceutically acceptable salt thereof, wherein R 2 It is a hydrogen atom.

7. The compound of formula (IM) according to claim 1, or a pharmaceutically acceptable salt thereof, wherein R 7a and R 7b They may be the same or different, and each is independently a hydrogen atom or a methyl group.

8. The compound of formula (IM) according to claim 1, or a pharmaceutically acceptable salt thereof, is selected from any of the following compounds: , , , , and .

9. A compound of general formula (IIMa) or a salt thereof: in: R 3 -C(O)NR 7a R 7b ; R 7a C 1-6 alkyl; t is 1; X, Y, ring B, R 7b and n as defined in claim 2.

10. A compound or a pharmaceutically acceptable salt thereof, selected from any of the following compounds: , , , , , , , , , and .

11. A method for preparing a compound of the general formula (IIM) according to claim 2 or a pharmaceutically acceptable salt thereof, the method comprising: A compound of general formula (IIMa) or a salt thereof undergoes a nucleophilic substitution reaction with a compound of general formula (IIMb) to give a compound of general formula (IIM) or a pharmaceutically usable salt thereof; in: L represents a halogen; G 1 G 2 G 3 X, Y, ring B, R 0 R 1 R 3 , t and n are as defined in claim 2.

12. The method according to claim 11, wherein L is a chlorine atom.

13. A pharmaceutical composition comprising a compound of formula (IM) according to any one of claims 1 to 8 or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers, diluents or excipients.

14. Use of the compound of general formula (IM) according to any one of claims 1 to 8, or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition according to claim 13, in the preparation of a PARP1 inhibitor.

15. Use of the compound of general formula (IM) according to any one of claims 1 to 8, or a pharmaceutically usable salt thereof, or the pharmaceutical composition according to claim 13, in the preparation of a medicament for the treatment and / or prevention of cancer, essential thrombocythemia, or polycythemia vera.

16. The use according to claim 15, wherein the cancer is selected from breast cancer, ovarian cancer, pancreatic cancer, prostate cancer, gastric cancer, colorectal cancer, lung cancer, kidney cancer, liver cancer, cervical cancer, endometrial cancer, myeloma, leukemia, lymphoma, acoustic neuroma, basal cell carcinoma, bile duct cancer, bladder cancer, brain cancer, bronchial cancer, sarcoma, chordoma, choriocarcinoma, craniopharyngioma, cystadenocarcinoma, embryonal carcinoma, hemangioendothelioma, ependymoma, epithelial carcinoma, esophageal cancer, testicular cancer, glioma, heavy chain disease, hemangioblastoma, medullary carcinoma, medulloblastoma, melanoma, meningioma, mesothelioma, neuroblastoma, midline carcinoma of NUT, bone cancer, nasopharyngeal carcinoma, oral cancer, thyroid cancer, pineal tumor, retinoblastoma, sebaceous gland carcinoma, seminoma, skin cancer, squamous cell carcinoma, synovoma, sweat gland carcinoma, Waldenström macroglobulinemia, and Wilms' tumor.

17. The use according to claim 15, wherein the cancer is selected from breast cancer, ovarian cancer, pancreatic cancer, prostate cancer, gastric cancer, colorectal cancer, and lung cancer.

18. The use according to claim 16, wherein the sarcoma is Ewing's tumor.

Citation Information

Patent Citations

  • Poly (ADP-Ribose) Polymerase (PARP) Inhibitors

    CN102341394A

  • PARP1 inhibitors

    WO2021013735A1

  • Compounds as PARP inhibitors

    WO2022228387A1